Daniel L. Flynn

Founder at Deciphera Pharmaceuticals, Inc.

Daniel L. Flynn

Daniel L. Flynn

Founder at Deciphera Pharmaceuticals, Inc.

Overview
Career Highlights

Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals LLC

RelSci Relationships

4290

Number of Boards

2

Birthday

1954

Age

67

Contact Data
Trying to get in touch with Daniel L. Flynn? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Daniel L. Flynn likely has professional access to. A relationship does not necessarily indicate a personal connection.

Adjuncat Clinical Professor at University of Michigan - Flint

Relationship likelihood: Strong

President & Chief Executive Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Senior Advisor, Life Sciences Team at Frazier Healthcare Partners

Relationship likelihood: Strong

Executive Vice President, Chief Financial Officer & Treasurer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Professor & Dean Emeritus at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Chief Financial Officer at Vividion Therapeutics, Inc.

Relationship likelihood: Strong

Former President & Chief Executive Officer at Eurofins Viracor, Inc.

Relationship likelihood: Strong

Senior Vice President, General Counsel at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Controller & Director at Americo Life, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Technical Officer at Deciphera Pharmaceuticals LLC

Relationship likelihood: Strong

Paths to Daniel L. Flynn
Potential Connections via
Relationship Science
You
Daniel L. Flynn
Founder at Deciphera Pharmaceuticals, Inc.
Education
PhD

The University of Kansas (KU) is a public research university and the largest university in the State of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The University was opened in 1866, under a charter granted by the Kansas Legislature in 1864.

Career History
Founder
2003 - Current

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Founder
2003 - Current

Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Professor
Current

The University of Kansas (KU) is a public research university and the largest university in the State of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The University was opened in 1866, under a charter granted by the Kansas Legislature in 1864.

Boards & Committees
Trustee
Current

University of Kansas Center for Research, Inc. develops and administrates sponsored university programs. The not-for-profit research foundation submits proposals for external support of research, instructional, and service projects. It also provides contract negotiation, proposal and post-award, facility construction and development, resources investment, and financial management support services. The company was founded in 1962 and is headquartered in Lawrence, KS.

Transactions
Details Hidden

Deciphera Pharmaceuticals LLC raised money in a private placement transaction

Details Hidden

Deciphera Pharmaceuticals LLC raised money in a private placement transaction

Investments
Details Hidden

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Daniel L. Flynn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Daniel L. Flynn's profile does not indicate a business or promotional relationship of any kind between RelSci and Daniel L. Flynn.